Gilead fourth-quarter hepatitis C drug sales plummet; company sees a further slowdown

Gilead Sciences on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition.
Source: CNBC

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>